Thrombotic thrombocytopenic purpura laboratory findings: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 23: Line 23:
* '''Serum creatinine:''' Increased
* '''Serum creatinine:''' Increased
* '''Urine output:''' Decreased  
* '''Urine output:''' Decreased  
* '''ADAMTS13 test: ADAMTS13 activity or inhibitor provides information for the diagnosis of the types and causes of TTP:'''
* '''ADAMTS13 test:''' ADAMTS13 activity or inhibitor provides information for the diagnosis of the types and causes of TTP;
** '''ADAMTS13 activity:''' Decreased to < 10% during acute episodes of TTP.   
** '''ADAMTS13 activity:''' Decreased to < 10% during acute episodes of TTP.   
** '''ADAMTS13 inhinbitors test:'''   
** '''ADAMTS13 inhinbitors test:'''   

Revision as of 21:46, 24 August 2018

Thrombotic thrombocytopenic purpura Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombotic thrombocytopenic purpura from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Peripheral Smear

Direct Coombs Test

von Willebrand Factor-cleaving Protease Activity

X-ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombotic thrombocytopenic purpura laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombotic thrombocytopenic purpura laboratory findings

CDC on Thrombotic thrombocytopenic purpura laboratory findings

Thrombotic thrombocytopenic purpura laboratory findings in the news

Blogs on Thrombotic thrombocytopenic purpura laboratory findings

Directions to Hospitals Treating Thrombotic thrombocytopenic purpura

Risk calculators and risk factors for Thrombotic thrombocytopenic purpura laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Saeedeh Kowsarnia M.D.[2]

Overview

Laboratory Findings

  • CBC shows:
    • Thrombocytopenia (median platelet count 10,000/microL)
    • Microangiopathic hemolytic anemia [1]:
Hemolytic anemia
  • LDH ↑
  • Indirect bilirubin ↑
  • Serum haptoglubin ↓
  • Retic count ↑
  • Combs tests negative
  • Hb ~7 g/dl, Hct ~21%
  • Peripheral blood smear: Schistocytes, including helmet cells and triangular cells, polychromasia, microspherocytes and nucleated RBCs
  • Urinalysis: Hematuria, proteinuria
  • Serum creatinine: Increased
  • Urine output: Decreased
  • ADAMTS13 test: ADAMTS13 activity or inhibitor provides information for the diagnosis of the types and causes of TTP;
    • ADAMTS13 activity: Decreased to < 10% during acute episodes of TTP.
    • ADAMTS13 inhinbitors test:
  • Genetic testing: Should be done in suspected cases of,
    • Positive family history
    • Recurrent episodes
    • Onset during childhood or pregnancy
    • Absence of inhibitors
    • Persistent ADAMTS13 deficiency
  • Imaging: In cases with higher suspicion of TTP, imaging is not necessary but with focal neurological signs MRI or CT may be considered
  • Blood culture: Patients with fever or signs and symptoms of infections
  • Stool exam: Stool culture and toxin evaluation should be considered in patients with diarrhea as one of the main presentation especially bloody diarrhea
  • Pathology: Tissue biopsy is not necessary for diagnosis, but it may show classic changes of a thrombotic microangiopathy including platelet microthrombi in small arterioles or capillaries, or hyaline changes in and around vessel walls.

References

  1. BRAIN MC, DACIE JV, HOURIHANE DO (1962). "Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis". Br J Haematol. 8: 358–74. PMID 14014893.

Template:WH Template:WS